All In Biotech

Drug Trial Radar · NCT07709897

A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting

A Multicenter, Randomized, Dose-finding, Positive-controlled, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS5580 for Injection Combined With Palonosetron Hydrochloride in the Prevention of Postoperative Nausea and Vomiting

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Aug 6, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for injection combined with palonosetron hydrochloride for the prevention of postoperative nausea and vomiting.

Conditions

  • Prevention of Postoperative Nausea and Vomiting

Interventions

  • HRS5580 for injection combined with palonosetron hydrochloride;Drug

    HRS5580 for injection combined with palonosetron hydrochloride; low dose

  • HRS5580 for injection combined with palonosetron hydrochlorideDrug

    HRS5580 for injection combined with palonosetron hydrochloride; high dose

  • HRS5580 for injection blank preparation combined with palonosetron hydrochlorideDrug

    HRS5580 for injection blank preparation combined with palonosetron hydrochloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response rate within 72 hours after extubation (defined as the proportion of participants with no vomiting and no use of rescue therapy)Time frame: within 72 hours after extubation

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University Zhongshan Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Nankai Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.